QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fulco, P. P. Articles by Kirian, M. A Search for Related Content PubMed PubMed Citation Articles by Fulco, P. P. Articles by Kirian, M. A

DRUG INFORMATION ROUNDS

Effect of Tenofovir on Didanosine Absorption in Patients with HIV

Clinical Specialist, Internal Medicine; Assistant Clinical Professor of Pharmacy, Virginia Commonwealth University Health System, Department of Pharmacy Services, Medical College of Virginia Hospitals and Physicians, Richmond, VA

Margaret A Kirian, PharmD

Pharmacy Practice Resident; Clinical Instructor of Pharmacy, Virginia Commonwealth University Health System

Reprints: Patricia Pecora Fulco PharmD BCPS, Department of Pharmacy Services, Medical College of Virginia Hospitals and Physicians, 401 N. 12th St., PO Box 980042, Richmond, VA 23298-0042, FAX 804/225-3920, pgpecora{at}hsc.vcu.edu

OBJECTIVE: To evaluate the pharmacokinetic interaction between tenofovir and didanosine when used in combination as a highly active antiretroviral therapy regimen.

DATA SOURCES: Literature retrieval was accessed through MEDLINE (1966–January 2003) using the terms tenofovir and didanosine. Abstracts from recent meetings, including the International AIDS Society, Interscience Conference on Antimicrobial Agents and Chemotherapy, and the Infectious Diseases Society of America, were reviewed for relevant abstracts and poster presentations.

DATA SYNTHESIS: Pharmacokinetic studies evaluating the concurrent use of tenofovir and didanosine have been performed in healthy volunteers. Tenofovir 300 mg administered concurrently with 400 mg didanosine results in a 48–64% increase in the didanosine maximum plasma concentration and AUC with no significant alterations in the tenofovir pharmacokinetic parameters. Tenofovir 300 mg and didanosine 250 mg has been compared with didanosine 400 mg alone. The results demonstrated equivalent didanosine AUCs.

CONCLUSIONS: When used concurrently, tenofovir significantly increases the maximum plasma concentration and the AUC of didanosine. Additional data in HIV-infected patients are needed to determine the long-term toxicities of this combination therapy. Didanosine dose reduction should be considered when these 2 agents are used concurrently.

Key Words: didanosine; interaction, pharmacokinetic; tenofovir

Published Online, July 2, 2003. www.theannals.com, DOI 10.1345/aph.1C412

This article has been cited by other articles:

				A. Pruvost, E. Negredo, F. Theodoro, J. Puig, M. Levi, R. Ayen, J. Grassi, and B. Clotet Pilot Pharmacokinetic Study of Human Immunodeficiency Virus-Infected Patients Receiving Tenofovir Disoproxil Fumarate (TDF): Investigation of Systemic and Intracellular Interactions between TDF and Abacavir, Lamivudine, or Lopinavir-Ritonavir Antimicrob. Agents Chemother., May 1, 2009; 53(5): 1937 - 1943. [Abstract] [Full Text] [PDF]

				F. Vidal, J. C. Domingo, J. Guallar, M. Saumoy, B. Cordobilla, R. Sanchez de la Rosa, M. Giralt, M. L. Alvarez, M. Lopez-Dupla, F. Torres, et al. In Vitro Cytotoxicity and Mitochondrial Toxicity of Tenofovir Alone and in Combination with Other Antiretrovirals in Human Renal Proximal Tubule Cells Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3824 - 3832. [Abstract] [Full Text] [PDF]

				P. Barreiro and V. Soriano Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir J. Antimicrob. Chemother., May 1, 2006; 57(5): 806 - 809. [Abstract] [Full Text] [PDF]

				A. Pruvost, E. Negredo, H. Benech, F. Theodoro, J. Puig, E. Grau, E. Garcia, J. Molto, J. Grassi, and B. Clotet Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1907 - 1914. [Abstract] [Full Text] [PDF]

				M. A Kirian, R. T Higginson, and P. P. Fulco Acute Onset of Pancreatitis with Concomitant Use of Tenofovir and Didanosine Ann. Pharmacother., October 1, 2004; 38(10): 1660 - 1663. [Abstract] [Full Text] [PDF]

				A. S. Ray, L. Olson, and A. Fridland Role of Purine Nucleoside Phosphorylase in Interactions between 2',3'-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1089 - 1095. [Abstract] [Full Text] [PDF]